TP53 and neoplasm: Especially, researchers proved that nutlin-3, a recently explored therapeutic agent targeted for TP53 wild-type OC (Zanjirband et al., 2017), had different efficiency according to patient’s TP53 status, indicating that organoids derived from a TP53 wild-type tumor were more sensitive to nutlin-3 (Maenhoudt et al., 2020).